Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Single Escalating Oral Doses of Gepotidacin in Healthy Adults
NCT02202187Phase 1Completed
- Sponsor
- GSK
- Start
- Sep 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in respiratory tract infection (RTI) and skin and soft tissue infections (SSTIs) comparing GSK2140944 with Placebo (2 arms). Primary endpoints: Change from baseline in 12-lead ECG, Clinical safety data from dual-lead cardiac monitoring at Day 1 and 4 more. Started Sep 2011; status: completed.
02
Drugs
gepotidacin
03
Conditions
respiratory tract infection (RTI)skin and soft tissue infections (SSTIs)
Beyond the preview
Go deeper on NCT02202187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02202187.